الصفحة الرئيسية>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Calcium Channel>>Carboxyamidotriazole Orotate

Carboxyamidotriazole Orotate (Synonyms: L-651582 Orotate; CAI Orotate)

رقم الكتالوجGC39646

Carboxyamidotriazole Orotate (L-651582 Orotate) هو شكل ملح orotate من Carboxyamidotriazole (CAI) ، وهو مثبط نقل الإشارة المتوفر بيولوجيًا عن طريق الفم

Products are for research use only. Not for human use. We do not sell to patients.

Carboxyamidotriazole Orotate التركيب الكيميائي

Cas No.: 187739-60-2

الحجم السعر المخزون الكميّة
5mg
180٫00
متوفر
10mg
270٫00
متوفر
50mg
765٫00
متوفر
100mg
1080٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor. Carboxyamidotriazole Orotate is a cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory and antiangiogenic effects[1][2].

[1]. Corrado C, et al. Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis. PLoS One. 2012;7(8):e42310. [2]. Hussain MM, et al. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol. 2003 Dec 1;21(23):4356-63.

مراجعات

Review for Carboxyamidotriazole Orotate

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Carboxyamidotriazole Orotate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.